Friday - May 23, 2025
Johnson & Johnson Receives FDA Approval for IMAAVY (nipocalimab-aahu), a New FcRn Blocker Offering Long-Lasting Disease Control in the Broadest Population of People Living With Generalized Myasthenia Gravis (gMG)
May 01, 2025
RARITAN, New Jersey, May 1 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:

* * *

Johnson & Johnson receives FDA approval for IMAAVY (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)

First and only FcRn blocker approved in anti-AChR and anti-MuS . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products